ALLMedicine™ Thymoma Center
Research & Reviews 952 results
https://doi.org/10.1016/j.jtcvs.2022.02.055
The Journal of Thoracic and Cardiovascular Surgery; Byrd CT, Trope WL et. al.
May 15th, 2022 - Discrete anterior mediastinal masses most often represent thymoma or lymphoma. Lymphoma treatment is nonsurgical and requires biopsy. Noninvasive thymoma is ideally resected without biopsy, which may potentiate pleural metastases. This study sough...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097348
Journal of Cardiothoracic Surgery; Zhou RQ, Li LJ et. al.
May 14th, 2022 - Post-thymectomy myasthenia gravis (PTMG) is defined as thymoma patients without signs of myasthenia gravis (MG) pre-operation, but develop MG after radical surgical resection. PTMG might be misdiagnosed not only because of its rare incidence, but ...
https://clinicaltrials.gov/ct2/show/NCT03739827
May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
https://clinicaltrials.gov/ct2/show/NCT03076554
May 13th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...
https://doi.org/10.12659/AJCR.936000
The American Journal of Case Reports; Kimura M, Nakagawa H et. al.
May 3rd, 2022 - BACKGROUND Myasthenia gravis (MG) is an autoimmune neuromuscular disorder, which is often accompanied by various complications. Partial dysgeusia is an uncommon nonmotor symptom of MG, and dysgeusia preceding typical MG symptoms is rare. Although ...
Clinicaltrials.gov 44 results
https://clinicaltrials.gov/ct2/show/NCT03076554
May 13th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...
https://clinicaltrials.gov/ct2/show/NCT03739827
May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...
https://clinicaltrials.gov/ct2/show/NCT02220855
Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...
https://clinicaltrials.gov/ct2/show/NCT01025089
Mar 8th, 2022 - The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thym...
https://clinicaltrials.gov/ct2/show/NCT01989598
Mar 2nd, 2022 - PRIMARY OBJECTIVES: I. To evaluate the antitumor activity of trametinib determined by overall response rate (ORR) in patients that are stratified into groups based on: biomarker positive (neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], v-...
News 35 results
https://www.onclive.com/view/tas-117-shows-limited-efficacy-in-ovarian-breast-tumors
Apr 11th, 2021 - Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog (Akt) inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in thos...
https://www.onclive.com/view/checkpoint-inhibitors-in-small-cell-lung-cancer
Apr 2nd, 2021 - Transcript: Mark A. Socinski, MD: One of the data sets that I thought was most encouraging at ASCO 2015 was the immunotherapeutic data for relapsed small-cell lung cancer where there’s a huge abyss of options. Roy, what were your thoughts about...
https://www.onclive.com/view/eltrombopag-improves-response-rates-in-severe-aplastic-anemia
Dec 20th, 2020 - Danielle M. Townsley, MD More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive thera...
https://www.onclive.com/view/teravolt-data-reveal-unexpectedly-high-mortality-in-patients-with-thoracic-cancers-and-covid19
Dec 20th, 2020 - Marina Chiara Garassino, MD Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population, Marina...
https://www.onclive.com/view/dr-riess-discusses-pd-l1-expression-in-thymic-malignancies
Dec 20th, 2020 - Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray. As PD-1 and PD-L1 antibodies have demonstrated benefit in other tum...